DBV Technologies - ADR
DBVT - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$896.64M
Close$
$2.00
79.9% downside
Current Fair Value
79.9% downsideOvervalued by 79.9% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $896.64 Million |
|---|---|
| Enterprise Value | $729.44 Million |
| Earnings per Share | $-1.7 |
| Beta | -0.21 |
| Outstanding Shares | 90,205,333 |
Return
| Return on Equity | -124.20% |
|---|---|
| Return on Assets | -89.25% |
| Return on Invested Capital | -90.76% |
Valuation & Multiples
| P/E Ratio | -3.18 |
|---|---|
| PEG | -2.8 |
| Price to Sales | - |
| Price to Book Ratio | 9.94 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -4.76 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.05 |
Revenue Sources
No data
Last Earnings Call
Report Date
October 28, 2026
EPS Estimate
$-0.60
Consensus analyst estimateRevenue Estimate
$558,221
Consensus analyst estimateNext Earnings Call
Expected Date
March 11, 2027
EPS Estimate
$-0.25
Consensus analyst estimateRevenue Estimate
$697,777
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.03%▼ 25.11% |
|---|---|
| Total Invested | $262,862▼ 99.92% |
| Investors Holding | 5▼ 73.00% |
About DBV Technologies
170 employees
CEO: Daniel Tasse
DBV Technologies S.A. is a clinical-stage biopharmaceutical company focusing on the research and development of epicutaneous immunotherapy products. Its flagship product candidate, Viaskin Peanut, an immunotherapy, has completed Phase II...